Skip to content

Journal of Personalized Medicine

ISSN 2075-4426

6 papers in the library · 46 citations · publishing 2022-2025

Papers

Sort Most recent Most cited

Enhancing Traumatic Stress Recovery Through Nonattachment Principles: A Scoping Review

Journal of Personalized Medicine December 9, 2025 Lindsay Tremblay, William van Gordon, James Elander 3 citations

Background: Nonattachment is an important component of Mindfulness-Based Interventions (MBIs), including its application within post-traumatic stress (PTS) contexts. However, within trauma contexts, there is limited understanding of the role and effectiveness of MBIs that integrate nonattachment. Objective: This study aimed to identify and evaluate evidence regarding the effectiveness of MBIs...

Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience)

Journal of Personalized Medicine April 1, 2025 Marco Di, M. Pepe, Giacomo D’andrea et al. 18 citations

Background. Treatment-resistant depression (TRD) is a prevalent, high-burden disorder. Esketamine nasal spray (ESK-NS) has been approved for, T.R.D.; and efficacy has been observed in both clinical trials and real-world studies. However, observations integrating patients’ perspective on this treatment are limited. This multicentric Italian study explored experiences with ESK-NS in TRD patients,...

Resilient Stress Reactivity Profiles Predict Mental Health Gains from Online Contemplative Training: A Randomized Clinical Trial.

Journal of Personalized Medicine May 4, 2024 Malvika Godara, Tania Singer 6 citations

Low-dose app-based contemplative interventions for mental health are increasingly popular, but heterogeneity in intervention responses indicates that a personalized approach is needed. We examined whether different longitudinal resilience-vulnerability trajectories, derived over the course of the COVID-19 pandemic, predicted differences in diverse mental health outcomes after mindfulness and...

Recent Developments in Pharmacotherapy of Depression: Bench to Bedside.

Journal of Personalized Medicine April 29, 2023 Mujeeb U Shad

For the last 70 years, we did not move beyond the monoamine hypothesis of depression until the approval of the S-enantiomer of ketamine, an N-methyl-D-aspartate (NMDA) receptor blocker and the first non-monoaminergic antidepressant characterized by rapid antidepressant and antisuicidal effects. A similar profile has been reported with another NMDA receptor antagonist, dextromethorphan, which...

Functional Neuroimaging in Dissociative Disorders: A Systematic Review.

Journal of Personalized Medicine August 29, 2022 Martina Nicole Modesti, Ludovica Rapisarda, Gabriela Capriotti et al.

Dissociative disorders encompass loss of integration in essential functions such as memory, consciousness, perception, motor control, and identity. Nevertheless, neuroimaging studies, albeit scarce, have suggested the existence of particular brain activation patterns in patients belonging to this diagnostic category. The aim of this review is to identify the main functional neuroimaging...

Psilocybin—Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience

Journal of Personalized Medicine June 19, 2022 Vojtěch Viktorin, Inga Griškova-bulanova, Aleksandras Voicikas et al. 19 citations

Psilocybin is a classical serotoninergic psychedelic that induces cognitive disruptions similar to psychosis. Gamma activity is affected in psychosis and is tightly related to cognitive processing. The 40 Hz auditory steady-state responses (ASSR) are frequently used as indicators to test the ability to generate gamma activity. Based on previous literature, we studied the impact of psilocybin on...